Anti-DDX31 Polyclonal Antibody for WB, IF/ICC, ELISA - Q9H8H2

Core Product Specifications and Parameters

Biological Background: DDX31 Function and Localization

• DDX31, also known as DEAD box protein 31 or Helicain, is a probable ATP-dependent RNA helicase (By similarity). It may possess both DNA and RNA helicase activities, along with ssDNA- and RNA-dependent ATPase activity (By similarity).
• DDX31 interacts with NPM1 (nucleophosmin) to regulate ribosome biogenesis and the tumor suppressor TP53/p53 (PubMed:23019224). Related references: PMID:23019224
• The protein localizes predominantly to the nucleolus within the nucleus, consistent with its role in ribosomal RNA processing.
• DDX31 expression is typically weak or undetectable in normal organs but is upregulated in renal cell carcinoma, suggesting potential as a cancer biomarker.
• The gene undergoes alternative initiation and alternative splicing, producing multiple isoforms with distinct N-termini.
• Key structural features include ATP-binding and RNA-binding domains, characteristic of DEAD-box helicases, and post-translational modifications such as methylation.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 652-851 near the C-terminus, which is less conserved among DEAD-box proteins, potentially enhancing specificity.
• In western blot (WB), a band around 94 kDa is expected; validate using lysates from renal carcinoma cell lines or tissues where DDX31 is upregulated.
• For immunofluorescence (IF/ICC), anticipate nucleolar staining; include appropriate controls and permeabilization methods.
• For ELISA, consider pairing with a monoclonal antibody for sandwich assays; optimize concentrations empirically.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive sourcing partner for IVD manufacturers, offering validated antibodies, bulk ancillary reagents, and rare target raw-material access. The DDX31 polyclonal antibody supports research into ribosome biogenesis and cancer diagnostics, aligning with CamelBio’s capability to supply high-quality immune reagents for diagnostic development, from concept to clinic.